Physician

Utkarsh Chris Shukla, MD

According to 2025 Medicare claims, Utkarsh Shukla, MD (NPI: 1437656154) practices radiation oncology in the Albuquerque, NM market, with the plurality of this provider's patient population coming from Bernalillo, NM. This provider's primary affiliated billing organization is NEW MEXICO ONCOLOGY HEMATOLOGY CONSULTANTS, LTD. (NPI: 1164475232; TIN: 850367056) and primary practice location at 87109-4495.

Shukla's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 270 traditional Medicare patients, billed 7,023 HCPCS/CPT codes, and received $848,191 in Medicare payments. The top billing code was G6015 (Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session). Part D data shows 269 prescription claims across 112 beneficiaries totaling $3,315 in drug costs, led by Mometasone Furoate (Mometasone Furoate). Open Payments data shows 9 records totaling $290. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $825 to $3,315. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$424K$848K2023 Medicare payment: $209,234 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $848,191 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
2021N/RN/RN/R
2022N/RN/RN/R
20231081,808$209,234
20242707,023$848,191

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$1.7K$3.3K2018 Drug cost: $825 (USD; Tot_Drug_Cst)2019 Drug cost: $1,318 (USD; Tot_Drug_Cst)2020 Drug cost: $921 (USD; Tot_Drug_Cst)2021 Drug cost: $521 (USD; Tot_Drug_Cst)2023 Drug cost: $1,044 (USD; Tot_Drug_Cst)2024 Drug cost: $3,315 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/R18$825
20191827$1,318
20202746$921
2021N/R18$521
2022N/RN/RN/R
20234070$1,044
2024112269$3,315

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
G6015Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session91535$249
77334Design and construction of complex radiation treatment device82266$92
77014Ct guidance for insertion of radiation therapy fields116702$87
77336Continuing radiation therapy consultation per week127254$62
77300Calculation of radiation therapy dose83259$49

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Mometasone FuroateMometasone Furoate37823$842
DexamethasoneDexamethasone19453$496
Lidocaine-PrilocaineLidocaine/Prilocaine19382$222
Tamsulosin HclTamsulosin Hcl21883$161
GabapentinGabapentin22830$154

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.9$290AstraZeneca Pharmaceuticals LP
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Utkarsh Chris Shukla, MD?

Tedicare shows public-source Medicare data for Utkarsh Chris Shukla, MD (NPI 1437656154), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Utkarsh Chris Shukla, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Utkarsh Chris Shukla, MD?

Utkarsh Chris Shukla, MD is linked to NEW MEXICO ONCOLOGY HEMATOLOGY CONSULTANTS, LTD. (billing NPI 1164475232) in the available physician profile data.

Does Utkarsh Chris Shukla, MD have Open Payments data?

Utkarsh Chris Shukla, MD has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.